Role of Growth Factors in Pancreatic Cancer

DOI: 10.1016/s1055-3207(18)30283-7
Surgical Oncology Clinics of North America, 1998, 7, 25-41.

#	Paper	IF	Citations
194	Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. *International Journal of Cancer*, **1998**, 78, 255-60	7.5	58
193	Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. **1998**, 28, 1038-49		86
192	Claudin-1 expression is induced by tumor necrosis factor-□n human pancreatic cancer cells. **1998**, 22, 645		1
191	Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. **1999**, 14, 577-84		25
190	Molecular aspects of pancreatic cancer and future perspectives. **1999**, 16, 281-90		70
189	Transgenic expression of epidermal growth factor and keratinocyte growth factor in beta-cells results in substantial morphological changes. **1999**, 162, 167-75		58
188	Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. **1999**, 19, 1363-71		77
187	Pancreatic Disease. **1999**,		
186	Immortalized pancreatic duct cells in vitro and in vivo. **1999**, 880, 50-65		15
185	Molecular pathology of invasive carcinoma. **1999**, 880, 74-82		13
184	Growth factors and cytokines in pancreatic carcinogenesis. **1999**, 880, 110-21		61
183	Potential alterations in gene expression associated with carcinogen exposure in Mya arenaria. **1999** , 4, 485-91		6
182	Pancreatic cancer. **1999**, 36, 57-152		37
181	Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. *Gastroenterology*, **1999**, 116, 1202-16	13.3	151
180	Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. *American Journal of Pathology*, **1999**, 155, 815-22	5.8	129
179	Fas and Fas-ligand expression in human pancreatic cancer. **2000**, 231, 368-79		41
178	Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. *International Journal of Cancer*, **2000**, 86, 399-407	7.5	93

177	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. *International Journal of Cancer*, **2000**, 88, 12-20	7.5	115
176	mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. **2000**, 30, 729-39		54
175	Pancreatic cancer: state-of-the-art care. **2000**, 50, 241-68		95
174	Current approaches and future strategies for pancreatic carcinoma. **2000**, 18, 43-56		30
173	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. **2000**, 97, 9624-9		221
172	Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.. **2000**, 5, 77		0
171	Experimental animal models of pancreatic cancer (review).. **2000**, 17, 217		1
170	Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. **2000**, 20, 935-46		68
169	Interleukin-8 and human cancer biology. **2001**, 12, 375-91		573
168	The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. **2001**, 503, 151-7		116
167	Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. *Pancreatology*, **2001**, 1, 517-24	3.8	37
166	Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. **2001**, 21, 529-37		28
165	Identification of disease-specific genes in chronic pancreatitis using DNA array technology. **2001**, 234, 769-78; discussion 778-9		49
164	Altered expression and localization of the tight junction protein ZO-1 in primary and metastatic pancreatic cancer. *Pancreas*, **2001**, 23, 259-65	2.6	45
163	Growth factors and their receptors in pancreatic cancer. **2001**, 21, 27-44		68
162	Mouse models of metastatic pancreatic adenocarcinoma. **2001**, 29, 25-35		13
161	A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. **2001**, 29, 37-46		24
160	Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells. **2001**, 29, 85-92		15

159	Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4. *Journal of Biological Chemistry*, **2001**, 276, 13461-8	5.4	24
158	An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. *Cancer Biology and Therapy*, **2002**, 1, 607-13	4.6	40
157	Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. *Pancreas*, **2002**, 24, 42-6	2.6	32
156	The Molecular Biology of Pancreatic Cancer. **2002**, 15-28		0
155	3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. *Gastroenterology*, **2002**, 122, 308-17	13.3	183
154	Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. *Gastroenterology*, **2002**, 122, 1898-912	13.3	43
153	IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. *Gastroenterology*, **2002**, 123, 301-13	13.3	31
152	Secretion of MUC5AC mucin from pancreatic cancer cells in response to forskolin and VIP. **2002**, 294, 680-6		11
151	Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. **2002**, 35, 138-47		78
150	Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. *British Journal of Cancer*, **2002**, 86, 257-62	8.7	56
149	Experimental animal models of pancreatic carcinogenesis and metastasis. **2003**, 33, 43-60		19
148	IGF-I receptor, cell-cell adhesion, tumour development and progression. **2004**, 35, 247-53		28
147	Dysregulation of beta-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. **2003**, 10, 284-90		55
146	Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. **2003**, 3, 565-76		584
145	Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. **2003**, 194, 108-16		74
144	Review article: chemotherapy for pancreatic cancer. **2003**, 18, 1049-69		52
143	Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. *Oncogene*, **2003**, 22, 319-29	9.2	446
142	Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. *Oncogene*, **2003**, 22, 6589-97	9.2	125

141	Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. *Gastroenterology*, **2003**, 124, 1830-45	13.3	80
140	Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. *Gastroenterology*, **2003**, 125, 891-905	13.3	205
139	Effects of STI571 (gleevec) on pancreatic cancer cell growth. **2003**, 2, 32		37
138	Apoptosis: targets in pancreatic cancer. **2003**, 2, 6		93
137	Pathways for aberrant angiogenesis in pancreatic cancer. **2003**, 2, 8		139
136	Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. *Pancreatology*, **2003**, 3, 293-302	3.8	10
135	Molecular pathogenesis of pancreatic cancer. **2003**, 4, 237-56		114
134	Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2. *Journal of Biological Chemistry*, **2003**, 278, 20574-81	5.4	21
133	Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. **2003**, 11, 305		19
132	Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. **2003**, 35, 14-24		6
131	Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. *Clinical Cancer Research*, **2004**, 10, 581-90	12.9	82
130	Autocrine motility factor signaling enhances pancreatic cancer metastasis. *Clinical Cancer Research*, **2004**, 10, 7775-84	12.9	67
129	Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer. **2004**, 24, 559		2
128	Gefitinib (Iressa, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. **2004**, 25, 203		5
127	Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. *Cancer Research*, **2004**, 64, 3599-606	10.1	55
126	Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers. *British Journal of Cancer*, **2004**, 90, 1198-203	8.7	51
125	Modern management of pancreatic carcinoma. **2004**, 34, 475-81		28
124	Expression of insulin-like growth factor-I receptor in primary cutaneous carcinomas. **2004**, 31, 368-72		4

123	Current status of gene therapy for pancreatic cancer. **2004**, 61, 84-92		5
122	Adenoviral gene therapy for pancreatic adenocarcinoma. **2004**, 61, 351-8		3
121	Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1. **2004**, 39, 224-35		35
120	NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. *International Journal of Cancer*, **2004**, 108, 181-8	7.5	101
119	Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. *International Journal of Cancer*, **2004**, 110, 584-8	7.5	70
118	Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. *International Journal of Cancer*, **2004**, 110, 668-76	7.5	79
117	Cell death pathways in pancreatitis and pancreatic cancer. *Pancreatology*, **2004**, 4, 567-86	3.8	115
116	Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. **2004**, 316, 71-7		69
115	Modulation of autonomic balance by tumors and viruses. **2004**, 63, 344-51		15
114	Pancreatic cancer. **2004**, 363, 1049-57		1569
113	Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines. *Pancreas*, **2004**, 28, 25-30	2.6	14
112	Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. *Pancreas*, **2004**, 29, 179-87	2.6	440
111	Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. *British Journal of Cancer*, **2005**, 92, 921-8	8.7	114
110	Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. **2005**, 7, 39-49		181
109	Localization of the human hedgehog-interacting protein (Hip) in the normal and diseased pancreas. **2005**, 42, 183-92		29
108	The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. *Journal of Cancer Research and Clinical Oncology*, **2005**, 131, 639-48	4.9	75
107	The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. *Cancer Research*, **2005**, 65, 11536-44	10.1	74
106	No association between dietary glycemic index or load and pancreatic cancer incidence in postmenopausal women. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1574-5	4	31

105	Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist. *Clinical Cancer Research*, **2005**, 11, 5665-7	12.9	12
104	Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. *Human Gene Therapy*, **2005**, 16, 1175-93	4.8	31
103	VAV1: a new target in pancreatic cancer?. *Cancer Biology and Therapy*, **2005**, 4, 509-11	4.6	17
102	Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. **2005**, 41, 846-57		102
101	SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells. *American Journal of Pathology*, **2005**, 166, 1379-92	5.8	47
100	Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. **2005**, 4, 14		77
99	Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. **2006**, 5, 1108-16		133
98	Pancreatic cancer: from bench to 5-year survival. *Pancreas*, **2006**, 33, 111-8	2.6	98
97	Estrogen receptors in pancreatic tumors. *Pancreas*, **2006**, 33, 119-27	2.6	31
96	Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). **2006**, 17, 1077-82		15
95	Development of radiolabeled peptides to target p185HER2/neu receptors of cancer. **2006**, 49, 1259-1271		2
94	Hsulf-1 regulates growth and invasion of pancreatic cancer cells. *Journal of Clinical Pathology*, **2006**, 59, 1052-8	3.9	29
93	Aberrant gata-3 expression in human pancreatic cancer. *Journal of Histochemistry and Cytochemistry*, **2006**, 54, 161-9	3.4	34
92	Molecular mechanisms of pancreatic cancer and potential targets of treatment. *Scandinavian Journal of Gastroenterology*, **2007**, 42, 279-96	2.4	4
91	Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. *Cancer Biology and Therapy*, **2007**, 6, 218-27	4.6	46
90	Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. *Cancer Biology and Therapy*, **2007**, 6, 1173-80	4.6	89
89	Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. *Cancer Research*, **2007**, 67, 10309-16	10.1	104
88	Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. *Cancer Letters*, **2007**, 255, 241-54	9.9	41

87	The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion. *Human Pathology*, **2007**, 38, 1590-602	3.7	21
86	Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. *Neoplasia*, **2007**, 9, 8-17	6.4	62
85	NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. *Gastroenterology*, **2007**, 133, 1637-48	13.3	127
84	Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. *International Journal of Cancer*, **2007**, 121, 21-32	7.5	66
83	Pancreatic cancer microenvironment. *International Journal of Cancer*, **2007**, 121, 699-705	7.5	162
82	Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. *Cancer Gene Therapy*, **2007**, 14, 19-29	5.4	14
81	Pancreatic carcinogenesis. *Pancreatology*, **2008**, 8, 110-25	3.8	144
80	Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. *Pancreatology* , **2008**, 8, 488-97	3.8	39
79	Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. *Clinical Cancer Research*, **2008**, 14, 3942-7	12.9	20
78	14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. *Clinical Cancer Research*, **2008**, 14, 7614-23	12.9	51
77	Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. *Journal of Clinical Investigation*, **2008**, 118, 89-99	15.9	128
76	Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. *Biomedical Research*, **2008**, 29, 99-103	1.5	21
75	Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. *Cancer Research*, **2009**, 69, 422-30	10.1	180
74	Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. *Anatomical Record*, **2009**, 292, 1122-7	2.1	25
73	Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. *International Journal of Colorectal Disease*, **2009**, 24, 57-67	3	29
72	Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. *British Journal of Cancer*, **2009**, 100, 1267-76	8.7	100
71	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. *Journal of Experimental and Clinical Cancer Research*, **2009**, 28, 35	12.8	7
70	Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. *Journal of Cancer Research and Clinical Oncology*, **2010**, 136, 639-50	4.9	19

69	Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results. *Cancer Science*, **2010**, 101, 2448-54	6.9	21
68	Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. *Cancer Gene Therapy*, **2010**, 17, 325-33	5.4	14
67	Aberrant Signaling Pathways in Pancreatic Cancer. **2010**, 2783-2798		
66	Pancreas. **2010**, 237-260		4
65	CCL20/CCR6 expression profile in pancreatic cancer. *Journal of Translational Medicine*, **2010**, 8, 45	8.5	45
64	Cell-Extracellular Matrix Interactions in Cancer. **2010**,		14
63	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. *Molecular and Cellular Endocrinology*, **2011**, 344, 1-24	4.4	60
62	RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2011**, 1816, 209-18	11.2	35
61	Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2550-3	2.9	7
60	NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. *Journal of Biological Chemistry*, **2011**, 286, 7779-7787	5.4	46
59	Changes in insulin-like growth factor-1 and IGF-binding protein-3 in camel plasma during dehydration in the presence and absence of losartan. *Comparative Clinical Pathology*, **2012**, 21, 1745-1749	0.9	
58	Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. *American Journal of Pathology*, **2012**, 180, 1928-41	5.8	52
57	RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer. *PLoS ONE*, **2012**, 7, e34582	3.7	33
56	Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. *Frontiers in Bioscience - Landmark*, **2012**, 17, 2059-69	2.8	64
55	Genetically engineered mouse models of pancreatic adenocarcinoma. *Molecular Oncology*, **2013**, 7, 232-47	7.9	111
54	The role of insulin and IGF system in pancreatic cancer. *Journal of Molecular Endocrinology*, **2013**, 50, R67-74	4.5	54
53	Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability. *Oncogene*, **2013**, 32, 3638-47	9.2	31
52	Molecular markers in pancreatic cancer diagnosis. *Clinica Chimica Acta*, **2013**, 418, 22-9	6.2	24

51	Epidemiologie und Karzinogenese des Pankreaskarzinoms. **2013**, 334-339		
50	Altered Signaling Pathways and Potential Therapeutic Targets in Pancreatic Cancer. **2014**, 2265-2273		
49	A mathematical model for pancreatic cancer growth and treatments. *Journal of Theoretical Biology*, **2014**, 351, 74-82	2.3	79
48	Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. *Oncogene*, **2014**, 33, 4485-95	9.2	54
47	microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF- actions. *Oncogene*, **2014**, 33, 4664-74	9.2	103
46	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. *International Journal of Oncology*, **2014**, 45, 311-21	4.4	7
45	Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. *Cancer Medicine*, **2015**, 4, 1091-100	4.8	8
44	TIP30: A Novel Tumor-Suppressor Gene. *Oncology Research*, **2014**, 22, 339-48	4.8	7
43	TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. *Oncotarget*, **2015**, 6, 7504-21	3.3	36
42	Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. *Nature Communications*, **2015**, 6, 6200	17.4	53
41	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. *Journal of Cancer*, **2016**, 7, 1497-514	4.5	55
40	Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. *Pancreas*, **2016**, 45, 228-33	2.6	2
39	Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 2159-71	4.9	19
38	Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. *Acta Biochimica Et Biophysica Sinica*, **2016**, 48, 1067-1074	2.8	34
37	Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions. *Cell Reports*, **2016**, 14, 2325-36	10.6	136
36	Combined targeting of TGF- EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. *Cancer Letters*, **2016**, 379, 143-53	9.9	26
35	Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. *Journal of Nutritional Biochemistry*, **2016**, 31, 77-87	6.3	33
34	Inhibition of pancreatic cancer cell migration by plasma anthocyanins isolated from healthy volunteers receiving an anthocyanin-rich berry juice. *European Journal of Nutrition*, **2017**, 56, 203-214		20

33	KRas, ROS and the initiation of pancreatic cancer. *Small GTPases*, **2017**, 8, 38-42	2.7	42
32	Identification of sennoside A as a novel inhibitor of the slingshot (SSH) family proteins related to cancer metastasis. *Pharmacological Research*, **2017**, 119, 422-430	10.2	32
31	Protein kinase D signaling in cancer: A friend or foe?. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 283-294	11.2	38
30	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. *Drugs and Aging*, **2017**, 34, 331-357	4.7	6
29	The role of the signaling pathway FGF/FGFR in pancreatic cancer. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*, **2017**, 11, 101-110	0.4	3
28	Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in Pancreatic Cancer. *Frontiers in Oncology*, **2017**, 7, 41	5.3	20
27	Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. *Frontiers in Bioscience - Landmark*, **2018**, 23, 626-639	2.8	27
26	In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2020**, 17, 1010-1018	3	6
25	Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
24	Curing pancreatic cancer. *Seminars in Cancer Biology*, **2021**, 76, 232-246	12.7	2
23	The Multifaceted Role of TGF-□ in Gastrointestinal Tumors. *Cancers*, **2021**, 13,	6.6	4
22	Aberrant Transforming Growth Factor-□ Signaling in Human Pancreatic Cancer: Translational Implications. **2008**, 523-535		1
21	Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. *Recent Results in Cancer Research*, **2003**, 161, 180-95	1.5	17
20	Smad4: gatekeeper gene in head and neck squamous cell carcinoma. *Journal of Clinical Investigation* , **2009**, 119, 3208-11	15.9	18
19	Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. *PLoS ONE*, **2012**, 7, e39684	3.7	24
18	Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. *PLoS ONE*, **2012**, 7, e40435	3.7	11
17	[Role of fibroblast growth factors in pancreatic cancer]. *Biomeditsinskaya Khimiya*, **2016**, 62, 622-629	0.8	3
16	Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells. *Oncotarget*, **2016**, 7, 66491-66511	3.3	22

15	Targeting Notch signaling in pancreatic cancer patients--rationale for new therapy. *Advances in Medical Sciences*, **2009**, 54, 136-42	2.8	22
14	Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. *Cancers*, **2015**, 7, 1785-805	6.6	18
13	Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts. *World Journal of Gastroenterology*, **2005**, 11, 516-20	5.6	10
12	Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma. *Oncology Letters*, **2020**, 19, 4133-4141	2.6	4
11	Characterization of the Bystander Effect of Somatostatin Receptor sst2 After In Vivo Gene Transfer into Human Pancreatic Cancer Cells. *Human Gene Therapy*, **2005**, 050921065448001	4.8	
10	Key Roles of TGF-and Smad3 in Prostate Cancer. **2008**, 229-246		
9	Molecular Signaling Pathways in Pancreatic Cancer. **2008**, 181-228		
8	Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer. **2010**, 275-305		
7	Smad4/TGF-Signaling Pathways in Pancreatic Cancer Pathogenesis. **2010**, 419-439		
6	Growth Factors and Transcription Factors in Pancreatic Cancer. **1999**, 205-221		
5	Regulation der Fibroblastenwachstumsfaktorenrezeptor-1 III-mRNA-Splicevarianten in Pankreaskarzinomzellen. **2007**, 101-104		
4	Insulin-Like Growth Factor (IGF)-1, IGF-Binding Protein-3, and Pancreatic Cancer in Male Smokers. *Cancer Epidemiology Biomarkers and Prevention*, **2004**, 13, 438-444	4	10
3	Ras Inhibition in Glioblastoma Down-regulates Hypoxia-Inducible Factor-1Causing Glycolysis Shutdown and Cell Death. *Cancer Research*, **2005**, 65, 999-1006	10.1	44
2	Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research. **2022**, 1-20		0
1	Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research. **2023**, 777-796		0